Therapeutic targets and new directions for antibodies developed for ovarian cancer |
| |
| Authors: | Heather J Bax Debra H Josephs Giulia Pellizzari James F Spicer Ana Montes |
| |
| Institution: | 1. St. John's Institute of Dermatology, Division of Genetics and Molecular Medicine, Faculty of Life Sciences and Medicine, King's College London &2. NIHR Biomedical Research Center at Guy's and St. Thomas' Hospital and King's College London, Guy's Hospital, King's College London, London, UK;3. Division of Cancer Studies, Faculty of Life Sciences and Medicine, King's College London, Guy's Hospital, London, UK;4. Division of Cancer Studies, Faculty of Life Sciences and Medicine, King's College London, Guy's Hospital, London, UK;5. Department of Medical Oncology, Guy's and St Thomas' NHS Foundation Trust, London, UK |
| |
| Abstract: | Antibody therapeutics against different target antigens are widely used in the treatment of different malignancies including ovarian carcinomas, but this disease still requires more effective agents. Improved understanding of the biological features, signaling pathways, and immunological escape mechanisms involved in ovarian cancer has emerged in the past few years. These advances, including an appreciation of the cross-talk between cancer cells and the patient's immune system, have led to the identification of new targets. In turn, potential antibody treatments with various mechanisms of action, including immune activation or toxin-delivery, that are directed at these targets have been developed. Here, we identify established as well as novel targets for antibodies in ovarian cancer, and discuss how they may provide fresh opportunities to identify interventions with enhanced therapeutic potential. |
| |
| Keywords: | Antibodies clinical trials immunotherapy immune checkpoint molecular-targeting ovarian cancer tumor-associated antigen tumor-promoting molecule vaccine |
|
|
